Polar Asset Management Partners’s AstraZeneca AZN Stock Holding History

Polar Asset Management Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,701	Closed	-$238K	–	684
2025 Q2	$238K	Sell	1,701 -2,264	-57%	-$317K	﹤0.01%	433
2025 Q1	$583K	Sell	3,965 -93,435	-96%	-$13.5M	0.01%	330
2024 Q4	$12.8M	Buy	+97,400	New	+$13.6M	0.15%	130
2023 Q1	–	Sell	-23,700	Closed	-$3.21M	–	1057
2022 Q4	$3.21M	Buy	+23,700	New	+$2.97M	0.04%	528

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Polar Asset Management Partners's AZN Position: Q3 2025 in Review

Polar Asset Management Partners sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 1,701 shares — an estimated $238K sold.

Polar Asset Management Partners first reported a position in AZN in Q4 2022 and held it in 4 quarters. The position peaked at $12.8M in Q4 2024. 1,289 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

Polar Asset Management Partners reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
Polar Asset Management Partners sold 1,701 AstraZeneca shares in Q3 2025, an estimated $238K.
Polar Asset Management Partners first reported a position in AstraZeneca in Q4 2022 and held it in 4 quarters.
Polar Asset Management Partners's AstraZeneca position peaked at $12.8M in Q4 2024.
1,289 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.